{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:16:13Z","timestamp":1794118573031,"version":"4.8.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40265-025-02204-x","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:17:06Z","timestamp":1752833826000},"page":"1081-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Managing Pain in Fibromyalgia: Current and Future Options"],"prefix":"10.1007","volume":"85","author":[{"given":"Hance","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-3175","authenticated-orcid":false,"given":"Mary-Ann","family":"Fitzcharles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"3","key":"2204_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe F, et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319\u201329.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2204_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/art.38905","volume":"67","author":"GT Jones","year":"2015","unstructured":"Jones GT, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568\u201375.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2204_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pec.2008.06.005","volume":"73","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114\u201320.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"2204_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2020.10.006","volume":"51","author":"BA Kleykamp","year":"2021","unstructured":"Kleykamp BA, et al. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum. 2021;51(1):166\u201374.","journal-title":"Semin Arthritis Rheum"},{"issue":"10289","key":"2204_CR5","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","volume":"397","author":"MA Fitzcharles","year":"2021","unstructured":"Fitzcharles MA, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098\u2013110.","journal-title":"Lancet"},{"issue":"7","key":"2204_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000507","volume":"157","author":"E Kosek","year":"2016","unstructured":"Kosek E, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382\u20136.","journal-title":"Pain"},{"issue":"4","key":"2204_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.081180","volume":"36","author":"F Wolfe","year":"2009","unstructured":"Wolfe F. Fibromyalgia wars. J Rheumatol. 2009;36(4):671\u20138.","journal-title":"J Rheumatol"},{"issue":"6","key":"2204_CR8","first-page":"841","volume":"10","author":"MB Yunus","year":"1983","unstructured":"Yunus MB. Fibromyalgia syndrome: a need for uniform classification. J Rheumatol. 1983;10(6):841\u20134.","journal-title":"J Rheumatol"},{"issue":"2","key":"2204_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160\u201372.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2204_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2204_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jpain.2018.10.008","volume":"20","author":"LM Arnold","year":"2019","unstructured":"Arnold LM, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611\u201328.","journal-title":"J Pain"},{"issue":"31","key":"2204_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039109","volume":"103","author":"A Agarwal","year":"2024","unstructured":"Agarwal A, et al. Physicians\u2019 knowledge, attitudes, and practices regarding fibromyalgia: a systematic review and meta-analysis of cross-sectional studies. Medicine (Baltimore). 2024;103(31): e39109.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2204_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acr.21896","volume":"65","author":"A Vincent","year":"2013","unstructured":"Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786\u201392.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2204_CR14","doi-asserted-by":"publisher","first-page":"15022","DOI":"10.1038\/nrdp.2015.22","volume":"1","author":"W H\u00e4user","year":"2015","unstructured":"H\u00e4user W, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022.","journal-title":"Nat Rev Dis Primers"},{"issue":"36","key":"2204_CR15","first-page":"46","volume":"151","author":"N Uceyler","year":"2009","unstructured":"Uceyler N, Hauser W, Sommer C. Fibromyalgia syndrome: diagnostic criteria and treatment. MMW Fortschr Med. 2009;151(36):46\u20139.","journal-title":"MMW Fortschr Med"},{"issue":"12","key":"2204_CR16","first-page":"742","volume":"152","author":"JN Ablin","year":"2013","unstructured":"Ablin JN, et al. Guidelines for the diagnosis and treatment of the fibromyalgia syndrome. Harefuah. 2013;152(12):742\u20137.","journal-title":"Harefuah"},{"key":"2204_CR17","unstructured":"Fitzcharles M-A, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. 2012. http:\/\/www.canadianpainsociety.ca\/pdf\/Fibromyalgia_Guidelines_2012.pdf. Accessed 20 May 2013."},{"issue":"2","key":"2204_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2204_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254642","volume":"16","author":"AWA Geraghty","year":"2021","unstructured":"Geraghty AWA, et al. Self-management for chronic widespread pain including fibromyalgia: a systematic review and meta-analysis. PLoS\u00a0One. 2021;16(7): e0254642.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"2204_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/imj.16257","volume":"54","author":"Z Warren","year":"2024","unstructured":"Warren Z, et al. Significant use of non-evidence-based therapeutics in a cohort of Australian fibromyalgia patients. Intern Med J. 2024;54(4):568\u201374.","journal-title":"Intern Med J"},{"issue":"10","key":"2204_CR21","volume":"15","author":"PR Ram","year":"2023","unstructured":"Ram PR, et al. Beyond the pain: a systematic narrative review of the latest advancements in fibromyalgia treatment. Cureus. 2023;15(10): e48032.","journal-title":"Cureus"},{"issue":"11","key":"2204_CR22","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/ijms18112483","volume":"18","author":"H Obata","year":"2017","unstructured":"Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18(11):2483.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2204_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","volume":"181","author":"RO Mascarenhas","year":"2021","unstructured":"Mascarenhas RO, et al. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis. JAMA Intern Med. 2021;181(1):104\u201312.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2204_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/11598970-000000000-00000","volume":"26","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user W, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297\u2013307.","journal-title":"CNS Drugs"},{"issue":"5","key":"2204_CR25","first-page":"CD014682","volume":"5","author":"H Birkinshaw","year":"2023","unstructured":"Birkinshaw H, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023;5(5):CD014682.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2204_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12939","volume":"5","author":"HM Farag","year":"2022","unstructured":"Farag HM, et al. Comparison of amitriptyline and US food and drug administration-approved treatments for fibromyalgia: a systematic review and network meta-analysis. JAMA Netw Open. 2022;5(5): e2212939.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2204_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.psy.41.2.104","volume":"41","author":"LM Arnold","year":"2000","unstructured":"Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41(2):104\u201313.","journal-title":"Psychosomatics"},{"issue":"3","key":"2204_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.121.000998","volume":"380","author":"K Singh","year":"2022","unstructured":"Singh K, et al. The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors. J Pharmacol Exp Ther. 2022;380(3):202\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2204_CR29","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","volume":"75","author":"S Lederman","year":"2023","unstructured":"Lederman S, et al. Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2023;75(11):2359\u201368.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2204_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.bja.2018.02.066","volume":"120","author":"M Chincholkar","year":"2018","unstructured":"Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120(6):1315\u201334.","journal-title":"Br J Anaesth"},{"key":"2204_CR31","first-page":"Cd010782","volume":"10","author":"N \u00dc\u00e7eyler","year":"2013","unstructured":"\u00dc\u00e7eyler N, et al. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:Cd010782.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2204_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/03007995.2018.1450743","volume":"34","author":"LM Arnold","year":"2018","unstructured":"Arnold LM, et al. An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr Med Res Opin. 2018;34(8):1397\u2013409.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2204_CR33","first-page":"Cd012188","volume":"1","author":"TE Cooper","year":"2017","unstructured":"Cooper TE, et al. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017;1(1):Cd012188.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2204_CR34","first-page":"Cd008314","volume":"2013","author":"PJ Wiffen","year":"2013","unstructured":"Wiffen PJ, et al. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;2013(8):Cd008314.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2204_CR35","first-page":"Cd010567","volume":"2013","author":"PJ Wiffen","year":"2013","unstructured":"Wiffen PJ, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia\u2014an overview of cochrane reviews. Cochrane Database Syst Rev. 2013;2013(11):Cd010567.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2204_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/msc.1670","volume":"21","author":"LF Valladales-Restrepo","year":"2023","unstructured":"Valladales-Restrepo LF, et al. Treatment patterns in fibromyalgia including the use of opioids. Musculoskelet Care. 2023;21(1):66\u201377.","journal-title":"Musculoskelet Care"},{"issue":"2","key":"2204_CR37","doi-asserted-by":"publisher","first-page":"2252037","DOI":"10.1080\/24740527.2023.2252037","volume":"7","author":"G De Clifford-Faug\u00e8re","year":"2023","unstructured":"De Clifford-Faug\u00e8re G, et al. Pain medications used by persons living with fibromyalgia: a comparison between the profile of a Quebec sample and clinical practice guidelines. Can J Pain. 2023;7(2):2252037.","journal-title":"Can J Pain"},{"issue":"Suppl 130(3)","key":"2204_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.55563\/clinexprheumatol\/qcyet7","volume":"39","author":"MA Fitzcharles","year":"2021","unstructured":"Fitzcharles MA, et al. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clin Exp Rheumatol. 2021;39(Suppl 130(3)):115\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"2204_CR39","doi-asserted-by":"publisher","first-page":"1217717","DOI":"10.1155\/2022\/1217717","volume":"2022","author":"HC Aster","year":"2022","unstructured":"Aster HC, et al. Analgesic medication in fibromyalgia patients: a cross-sectional study. Pain Res Manag. 2022;2022:1217717.","journal-title":"Pain Res Manag"},{"issue":"3","key":"2204_CR40","first-page":"Cd012332","volume":"3","author":"S Derry","year":"2017","unstructured":"Derry S, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;3(3):Cd012332.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2204_CR41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/acr.22071","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (Hoboken). 2013;65(11):1813\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2204_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","volume":"17","author":"F Wolfe","year":"2013","unstructured":"Wolfe F, et al. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17(4):581\u20136.","journal-title":"Eur J Pain"},{"key":"2204_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fnins.2020.00512","volume":"14","author":"N \u00dc\u00e7eyler","year":"2020","unstructured":"\u00dc\u00e7eyler N, et al. Cortical binding potential of opioid receptors in patients with fibromyalgia syndrome and reduced systemic interleukin-4 levels\u2014a pilot study. Front Neurosci. 2020;14:512.","journal-title":"Front Neurosci"},{"issue":"37","key":"2204_CR44","doi-asserted-by":"publisher","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","volume":"27","author":"RE Harris","year":"2007","unstructured":"Harris RE, et al. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000\u20136.","journal-title":"J Neurosci"},{"issue":"3","key":"2204_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13455","volume":"74","author":"AP da Rocha","year":"2020","unstructured":"da Rocha AP, et al. Tramadol for management of fibromyalgia pain and symptoms: systematic review. Int J Clin Pract. 2020;74(3): e13455.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"2204_CR46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/14656566.2024.2365326","volume":"25","author":"P Sarzi-Puttini","year":"2024","unstructured":"Sarzi-Puttini P, et al. Pharmacotherapeutic advances in fibromyalgia: what\u2019s new on the horizon? Expert Opin Pharmacother. 2024;25(8):999\u20131017.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"2204_CR47","doi-asserted-by":"publisher","first-page":"e004466","DOI":"10.1136\/rmdopen-2024-004466","volume":"10","author":"I Hurtado","year":"2024","unstructured":"Hurtado I, et al. Long versus short-term opioid therapy for fibromyalgia syndrome and risk of depression, sleep disorders and suicidal ideation: a population-based, propensity-weighted cohort study. RMD Open. 2024;10(3):e004466.","journal-title":"RMD Open"},{"issue":"4","key":"2204_CR48","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10129","volume":"4","author":"PG Fine","year":"2013","unstructured":"Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4(4): e0022.","journal-title":"Rambam Maimonides Med J"},{"issue":"2","key":"2204_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/ph16020148","volume":"16","author":"B Rezende","year":"2023","unstructured":"Rezende B, et al. Endocannabinoid system: chemical characteristics and biological activity. Pharmaceuticals (Basel). 2023;16(2):148.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2204_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Z Atakan","year":"2012","unstructured":"Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241\u201354.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"2204_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","volume":"9","author":"S Atalay","year":"2019","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9(1):21.","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"2204_CR52","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpain.2020.12.001","volume":"22","author":"KF Boehnke","year":"2021","unstructured":"Boehnke KF, et al. Cannabidiol use for fibromyalgia: prevalence of use and perceptions of effectiveness in a large online survey. J Pain. 2021;22(5):556\u201366.","journal-title":"J Pain"},{"issue":"4","key":"2204_CR53","doi-asserted-by":"publisher","first-page":"E637","DOI":"10.9778\/cmajo.20180109","volume":"6","author":"W Alkabbani","year":"2018","unstructured":"Alkabbani W, et al. Pharmaceutical cannabinoid use in Manitoba, 2004\/05 to 2014\/15: a population-based cross-sectional study. CMAJ Open. 2018;6(4):E637-e642.","journal-title":"CMAJ Open"},{"issue":"6","key":"2204_CR54","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biomedicines11061621","volume":"11","author":"NH Strand","year":"2023","unstructured":"Strand NH, et al. Cannabis for the treatment of fibromyalgia: a systematic review. Biomedicines. 2023;11(6):1621.","journal-title":"Biomedicines"},{"key":"2204_CR55","volume":"16","author":"V Lopera","year":"2024","unstructured":"Lopera V, Restrepo JC, Amariles P. Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: a systematic review. Explor Res Clin Soc Pharm. 2024;16: 100524.","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"7","key":"2204_CR56","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/acr.24985","volume":"75","author":"R Sotoodeh","year":"2023","unstructured":"Sotoodeh R, et al. Predictors of pain reduction among fibromyalgia patients using medical cannabis: a long-term prospective cohort study. Arthritis Care Res (Hoboken). 2023;75(7):1588\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"2204_CR57","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/pm\/pnaa303","volume":"21","author":"C Chaves","year":"2020","unstructured":"Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-rich cannabis oil in people with fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial. Pain Med. 2020;21(10):2212\u20138.","journal-title":"Pain Med"},{"issue":"4","key":"2204_CR58","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860\u20139.","journal-title":"Pain"},{"issue":"2","key":"2204_CR59","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604\u201310.","journal-title":"Anesth Analg"},{"issue":"2","key":"2204_CR60","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek RQ, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164\u201373.","journal-title":"J Pain"},{"issue":"11","key":"2204_CR61","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jpain.2021.04.011","volume":"22","author":"KF Boehnke","year":"2021","unstructured":"Boehnke KF, et al. Substituting cannabidiol for opioids and pain medications among individuals with fibromyalgia: a large online survey. J Pain. 2021;22(11):1418\u201328.","journal-title":"J Pain"},{"issue":"7","key":"2204_CR62","first-page":"Cd011694","volume":"7","author":"B Walitt","year":"2016","unstructured":"Walitt B, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7(7):Cd011694.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2204_CR63","volume":"13","author":"H Khurshid","year":"2021","unstructured":"Khurshid H, et al. A systematic review of fibromyalgia and recent advancements in treatment: is medicinal cannabis a new hope? Cureus. 2021;13(8): e17332.","journal-title":"Cureus"},{"issue":"1","key":"2204_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00482-015-0084-3","volume":"30","author":"MA Fitzcharles","year":"2016","unstructured":"Fitzcharles MA, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30(1):47\u201361.","journal-title":"Schmerz"},{"issue":"5","key":"2204_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11926-022-01065-7","volume":"24","author":"WB Nowell","year":"2022","unstructured":"Nowell WB, Gavigan K. Cannabis for rheumatic disease pain: a review of current literature. Curr Rheumatol Rep. 2022;24(5):119\u201331.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"2204_CR66","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1097\/j.pain.0000000000003140","volume":"165","author":"A Moore","year":"2024","unstructured":"Moore A, et al. Narrative bias (\u201cspin\u201d) is common in randomised trials and systematic reviews of cannabinoids for pain. Pain. 2024;165(6):1380\u201390.","journal-title":"Pain"},{"issue":"2","key":"2204_CR67","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1089\/can.2021.0156","volume":"9","author":"AD Bell","year":"2024","unstructured":"Bell AD, et al. Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions. Cannabis Cannabinoid Res. 2024;9(2):669\u201387.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"2204_CR68","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0304-3959(99)00308-5","volume":"85","author":"T Graven-Nielsen","year":"2000","unstructured":"Graven-Nielsen T, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85(3):483\u201391.","journal-title":"Pain"},{"issue":"4","key":"2204_CR69","doi-asserted-by":"publisher","first-page":"387","DOI":"10.31486\/toj.21.0038","volume":"21","author":"M Pastrak","year":"2021","unstructured":"Pastrak M, et al. Systematic review of the use of intravenous ketamine for fibromyalgia. Ochsner J. 2021;21(4):387\u201394.","journal-title":"Ochsner J"},{"issue":"1","key":"2204_CR70","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s42358-024-00393-9","volume":"64","author":"JF de Carvalho","year":"2024","unstructured":"de Carvalho JF, de Sena EP. Ketamine in fibromyalgia: a systematic review. Adv Rheumatol. 2024;64(1):54.","journal-title":"Adv Rheumatol"},{"issue":"5","key":"2204_CR71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ejp.794","volume":"20","author":"SE van der Wal","year":"2016","unstructured":"van der Wal SE, et al. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. Eur J Pain. 2016;20(5):655\u201374.","journal-title":"Eur J Pain"},{"issue":"4","key":"2204_CR72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.5498\/wjp.v12.i4.615","volume":"12","author":"JF de Carvalho","year":"2022","unstructured":"de Carvalho JF, Skare TL. Lidocaine in fibromyalgia: a systematic review. World J Psychiatry. 2022;12(4):615\u201322.","journal-title":"World J Psychiatry"},{"issue":"3","key":"2204_CR73","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/1570159X14666161228122115","volume":"15","author":"S Tordjman","year":"2017","unstructured":"Tordjman S, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434\u201343.","journal-title":"Curr Neuropharmacol"},{"key":"2204_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2019.101072","volume":"38","author":"K Hemati","year":"2020","unstructured":"Hemati K, et al. Melatonin in the treatment of fibromyalgia symptoms: a systematic review. Complement Ther Clin Pract. 2020;38: 101072.","journal-title":"Complement Ther Clin Pract"},{"issue":"12","key":"2204_CR75","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.pain.2014.09.004","volume":"155","author":"B Olivan-Bl\u00e1zquez","year":"2014","unstructured":"Olivan-Bl\u00e1zquez B, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain. 2014;155(12):2517\u201325.","journal-title":"Pain"},{"issue":"11","key":"2204_CR76","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/cns.12314","volume":"20","author":"N Fayed","year":"2014","unstructured":"Fayed N, et al. Changes in metabolites after treatment with memantine in fibromyalgia. A double-blind randomized controlled trial with magnetic resonance spectroscopy with a 6-month follow-up. CNS Neurosci Ther. 2014;20(11):999\u20131007.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"2204_CR77","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/ejp.1393","volume":"23","author":"R Kurian","year":"2019","unstructured":"Kurian R, Raza K, Shanthanna H. A systematic review and meta-analysis of memantine for the prevention or treatment of chronic pain. Eur J Pain. 2019;23(7):1234\u201350.","journal-title":"Eur J Pain"},{"issue":"4","key":"2204_CR78","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"J Younger","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451\u20139.","journal-title":"Clin Rheumatol"},{"key":"2204_CR79","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/JPR.S395457","volume":"16","author":"J Yang","year":"2023","unstructured":"Yang J, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review. J Pain Res. 2023;16:1017\u201323.","journal-title":"J Pain Res"},{"issue":"5","key":"2204_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15638","volume":"9","author":"S Partridge","year":"2023","unstructured":"Partridge S, et al. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon. 2023;9(5): e15638.","journal-title":"Heliyon"},{"issue":"1","key":"2204_CR81","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","volume":"6","author":"K Due Bruun","year":"2024","unstructured":"Due Bruun K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31\u20139.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"2204_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001080","volume":"8","author":"K Bested","year":"2023","unstructured":"Bested K, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023;8(4): e1080.","journal-title":"Pain Rep"},{"issue":"4","key":"2204_CR83","first-page":"409","volume":"73","author":"TMH Paula","year":"2023","unstructured":"Paula TMH, et al. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial. Braz J Anesthesiol. 2023;73(4):409\u201317.","journal-title":"Braz J Anesthesiol"},{"issue":"1","key":"2204_CR84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/02791072.2021.2022817","volume":"55","author":"NG Glynos","year":"2023","unstructured":"Glynos NG, et al. Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. J Psychoact Drugs. 2023;55(1):73\u201384.","journal-title":"J Psychoact Drugs"},{"key":"2204_CR85","doi-asserted-by":"publisher","first-page":"1527783","DOI":"10.3389\/fpain.2025.1527783","volume":"6","author":"JS Aday","year":"2025","unstructured":"Aday JS, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res (Lausanne). 2025;6:1527783.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"4","key":"2204_CR86","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/ALN.0000000000004673","volume":"139","author":"A Goel","year":"2023","unstructured":"Goel A, et al. Use of psychedelics for pain: a scoping review. Anesthesiology. 2023;139(4):523\u201336.","journal-title":"Anesthesiology"},{"key":"2204_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109528","volume":"233","author":"FZ Zia","year":"2023","unstructured":"Zia FZ, et al. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Neuropharmacology. 2023;233: 109528.","journal-title":"Neuropharmacology"},{"key":"2204_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120302","volume":"439","author":"RL Henner","year":"2022","unstructured":"Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022;439: 120302.","journal-title":"J Neurol Sci"},{"key":"2204_CR89","first-page":"55","volume":"113","author":"U Haus","year":"2000","unstructured":"Haus U, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol Suppl. 2000;113:55\u20138.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"3","key":"2204_CR90","first-page":"113","volume":"27","author":"T Stratz","year":"2001","unstructured":"Stratz T, et al. Fibromyalgia treatment with intravenous tropisetron administration. Drugs Exp Clin Res. 2001;27(3):113\u20138.","journal-title":"Drugs Exp Clin Res"},{"issue":"1","key":"2204_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/BMR-200282","volume":"35","author":"I Hernando-Garijo","year":"2022","unstructured":"Hernando-Garijo I, et al. Effectiveness of non-pharmacological conservative therapies in adults with fibromyalgia: a systematic review of high-quality clinical trials. J Back Musculoskelet Rehabil. 2022;35(1):3\u201320.","journal-title":"J Back Musculoskelet Rehabil"},{"key":"2204_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152248","volume":"63","author":"J Bidonde","year":"2023","unstructured":"Bidonde J, et al. Effectiveness of non-pharmacological interventions for fibromyalgia and quality of review methods: an overview of Cochrane Reviews. Semin Arthritis Rheum. 2023;63: 152248.","journal-title":"Semin Arthritis Rheum"},{"issue":"15","key":"2204_CR93","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.3390\/jcm11154324","volume":"11","author":"G Varallo","year":"2022","unstructured":"Varallo G, et al. Is Whole-body cryostimulation an effective add-on treatment in individuals with fibromyalgia and obesity? A randomized controlled clinical trial. J Clin Med. 2022;11(15):4324.","journal-title":"J Clin Med"},{"key":"2204_CR94","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ctim.2017.10.011","volume":"36","author":"M Vitenet","year":"2018","unstructured":"Vitenet M, et al. Effect of whole body cryotherapy interventions on health-related quality of life in fibromyalgia patients: a randomized controlled trial. Complement Ther Med. 2018;36:6\u20138.","journal-title":"Complement Ther Med"},{"issue":"8","key":"2204_CR95","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/jpm14080836","volume":"14","author":"F Verme","year":"2024","unstructured":"Verme F, et al. Whole-body cryostimulation: an effective complementary treatment in fibromyalgia? A follow up study. J Pers Med. 2024;14(8):836.","journal-title":"J Pers Med"},{"issue":"1","key":"2204_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s42358-020-00159-z","volume":"61","author":"P Klemm","year":"2021","unstructured":"Klemm P, et al. Serial whole-body cryotherapy in fibromyalgia is effective and alters cytokine profiles. Adv Rheumatol. 2021;61(1):3.","journal-title":"Adv Rheumatol"},{"issue":"3","key":"2204_CR97","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/nu15030716","volume":"15","author":"EK Maddox","year":"2023","unstructured":"Maddox EK, et al. Dietary effects on pain symptoms in patients with fibromyalgia syndrome: systematic review and future directions. Nutrients. 2023;15(3):716.","journal-title":"Nutrients"},{"key":"2204_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinph.2023.01.011","volume":"148","author":"YC Cheng","year":"2023","unstructured":"Cheng YC, et al. Treating fibromyalgia with electrical neuromodulation: a systematic review and meta-analysis. Clin Neurophysiol. 2023;148:17\u201328.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"2204_CR99","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12883-023-03445-7","volume":"23","author":"R Moshfeghinia","year":"2023","unstructured":"Moshfeghinia R, et al. The effects of transcranial direct-current stimulation (tDCS) on pain intensity of patients with fibromyalgia: a systematic review and meta-analysis. BMC Neurol. 2023;23(1):395.","journal-title":"BMC Neurol"},{"issue":"4","key":"2204_CR100","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neurom.2022.10.044","volume":"26","author":"PEP Teixeira","year":"2023","unstructured":"Teixeira PEP, et al. The analgesic effect of transcranial direct current stimulation in fibromyalgia: a systematic review, meta-analysis, and meta-regression of potential influencers of clinical effect. Neuromodulation. 2023;26(4):715\u201327.","journal-title":"Neuromodulation"},{"issue":"3","key":"2204_CR101","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/pm\/pnab276","volume":"23","author":"P Sun","year":"2022","unstructured":"Sun P, et al. Repetitive transcranial magnetic stimulation for patients with fibromyalgia: a systematic review with meta-analysis. Pain Med. 2022;23(3):499\u2013514.","journal-title":"Pain Med"},{"issue":"1","key":"2204_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/17581869.2025.2459594","volume":"15","author":"A Leenus","year":"2025","unstructured":"Leenus A, et al. Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis. Pain Manag. 2025;15(1):45\u201353.","journal-title":"Pain Manag"},{"issue":"7","key":"2204_CR103","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jmpt.2011.05.006","volume":"34","author":"L Terhorst","year":"2011","unstructured":"Terhorst L, et al. Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. J Manip Physiol Ther. 2011;34(7):483\u201396.","journal-title":"J Manip Physiol Ther"},{"issue":"4","key":"2204_CR104","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.mayocpiqo.2019.07.003","volume":"3","author":"AB Mohabbat","year":"2019","unstructured":"Mohabbat AB, et al. Use of complementary and integrative therapies by fibromyalgia patients: a 14-year follow-up study. Mayo Clin Proc Innov Qual Outcomes. 2019;3(4):418\u201328.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"2204_CR105","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.pmn.2020.07.003","volume":"21","author":"AR Pfalzgraf","year":"2020","unstructured":"Pfalzgraf AR, et al. Use of complementary and alternative medicine in fibromyalgia: results of an online survey. Pain Manag Nurs. 2020;21(6):516\u201322.","journal-title":"Pain Manag Nurs"},{"issue":"9","key":"2204_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2024.104535","volume":"25","author":"H Fang","year":"2024","unstructured":"Fang H, et al. Fecal microbiota transplantation improves clinical symptoms of fibromyalgia: an open-label, randomized, nonplacebo-controlled study. J Pain. 2024;25(9): 104535.","journal-title":"J Pain"},{"issue":"1","key":"2204_CR107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14656566.2021.1970135","volume":"23","author":"JV Pergolizzi Jr","year":"2022","unstructured":"Pergolizzi JV Jr, et al. Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity. Expert Opin Pharmacother. 2022;23(1):105\u201316.","journal-title":"Expert Opin Pharmacother"},{"key":"2204_CR108","doi-asserted-by":"publisher","first-page":"6541798","DOI":"10.1155\/2020\/6541798","volume":"2020","author":"R Tzadok","year":"2020","unstructured":"Tzadok R, Ablin JN. Current and emerging pharmacotherapy for fibromyalgia. Pain Res Manag. 2020;2020:6541798.","journal-title":"Pain Res Manag"},{"issue":"6 Suppl 74","key":"2204_CR109","first-page":"78","volume":"30","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user W, et al. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol. 2012;30(6 Suppl 74):78\u201387.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02204-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:07:14Z","timestamp":1757254034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02204-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2204"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02204-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"4 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and were in compliance with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}},{"value":"Hance Clarke is funded via a Merit Award from the Department of Anesthesiology and Pain Medicine at the University of Toronto and is president of the Canadian Pain Society and the president of the Canadian Consortium for the Investigation of Cannabinoids. Miki Peer and Sarah Miles declare that they have no conflicts of interest that might be relevant to the contents of this article. Mary-Ann Fitzcharles was a Core member of the Health Canada Science Advisory Committee on Health Products Containing Cannabis (SAC-HPCC) 2020\u20132022, lead on the Canadian Rheumatology Association position statement on cannabis for the rheumatology patient and lead on the Canadian Fibromyalgia Guidelines, and has no other conflicts of interest that might be relevant to the contents of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"All of the listed authors contributed to the literature search and evaluation of current publications and participated in the writing of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}